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Available online 3 October 2014Hepatic steatosis (or fatty liver) is a common histological
finding in patients with metabolic syndrome, alcoholic
hepatitis, or hepatitis C, or those who receive certain drugs
such as steroids and amiodarone. The complication of he-
patic steatosis in patients with other liver diseases such as
hepatitis C leads to the progression of liver fibrosis and poor
treatment response. Therefore, an accurate evaluation of
hepatic steatosis is essential for clinical decision making
and prognosis assessment. Abdominal ultrasonography is a
highly accurate and commonly used tool for diagnosing
fatty liver. The diagnostic criteria of this technique include
the following: brightness contrast between the liver pa-
renchyma and the right renal cortex; masking of the portal
vein, hepatic vein, and gallbladder wall; and ultrasound
attenuation in deep liver tissues. However, ultrasound has
low sensitivity in diagnosing mild steatosis and is prone to
the operator’s subjective opinion. Although computed to-
mography and magnetic resonance imaging play a certain
role in diagnosing fatty liver, these techniques are limited
by availability and radiation exposure. Computed tomog-
raphy is suitable only for detecting steatosis with >30% fat
accumulation. Although magnetic resonance imaging offers
outstanding accuracy, it is less suited for regular screeningConflicts of interest: The authors declare no conflicts of
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Currently, the gold standard for steatosis assessment is liver
biopsy; however, it is invasive, costly, prone to sampling
bias, and risks potential serious complications. Further-
more, in the clinical setting, repeated biopsies are not a
feasible method for following up on the status of steatosis.
To overcome these limitations, Fibroscan ( 502 Touch by
Echosens (Paris, France)), a technology based on liver
fibrosis, has been developed.
The measurement of ultrasound attenuation during
transmission through biological tissues has multiple useful
biomedical applications. Ultrasound attenuation, the en-
ergy loss when the sound wave passes through a medium,
depends on: (1) the frequency of the ultrasound; and (2)
the nature of the transmission medium. The standard ul-
trasound attenuation rates at 3.5 MHz in different human
tissues are as follows: 175e630 dB/m in fat, 40e70 dB/m in
liver, 315e385 dB/m in tendons, and 105e280 dB/m in soft
tissues. Based on ultrasound attenuation principles and the
effect of fat on attenuation, researchers developed a new
method, named controlled attenuation parameter (CAP), to
quantify the degree of steatosis in liver tissue [1]. This
technology uses Vibration-Controlled Transient Elastog-
raphy (VCTE), which emits ultrasound at a fixed center
frequency of 3.5 MHz and traces the velocity of shear waves
to measure liver firmness. In addition, CAP uses the fre-
quency data collected from the same examination area to
assess the total attenuation of the ultrasound signal,
including the paths from and to the probe. The result is
expressed in dB/m, ranging from 100 dB/m to 400 dB/m (aof Ultrasound in Medicine. Open access under CC BY-NC-ND license.
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The CAP technology is noninvasive, is easy to use, and
provides real-time surveillance. Furthermore, because the
procedure can monitor an area 100 times that of liver bi-
opsy, it eliminates operator sampling bias. Fibroscan allows
the clinician to evaluate and quantify steatosis while
assessing fibrosis, thus facilitating post-treatment compar-
ison through follow ups.
Myers et al [2] analyzed 153 patients who received liver
biopsy and CAP-coupled Fibroscan simultaneously. They
found that patients with a higher degree and proportion of
steatosis confirmed by liver biopsy also had higher CAP
scores. A recent large-scale study (comprising 5323 tests)
found CAP scores associated with clinical disease presen-
tation and blood test values. Researchers found that pa-
tients with fatty liver-triggering conditions such as
metabolic syndrome, alcoholism, hypertriglyceridemia,
large abdominal circumference, diabetes or hypertension,
and high body mass index (>30 kg/m2) had increased CAP
values accordingly. CAP areas under the receiver operating
characteristic curve were 0.79 [95% confidence interval
(CI), 0.74e0.84; p < 0.001], 0.84 (95% CI, 0.80e0.88,
p < 0.001), and 0.84 (95% CI, 0.80e0.88, p < 0.001) in
patients with >10%, >33%, and >66% steatosis, respectively
[3]. Other clinical studies also showed CAP examination to
be free from operator bias. In a prospective study, two
independent operators performed CAP examinations on 118
patients. The results revealed good consistency between
the CAP data from the two operators, with an intraclass
correlation coefficient of 0.84 (95% CI, 0.77e0.88) [4]. In
addition, CAP can be used to diagnose fatty liver regardless
of etiology. One study recruited 146 patients with chronic
hepatitis B, 180 with chronic hepatitis C, and 63 with
nonalcoholic fatty liver; all 389 patients received liver bi-
opsy and CAP examination. CAP showed areas under the
receiver operating characteristic curve of 0.683, 0.793, and0.841 in chronic hepatitis B patients with 6 %, >33%, and
>66% steatosis, respectively. In addition, the accuracy of
diagnosing fatty liver did not differ significantly between
groups [5].
Fibroscan coupled with CAP shows promise as a nonin-
vasive tool for assessing liver fibrosis and steatosis. Spe-
cifically, as this technology provides longitudinal data, it
can be effectively used to evaluate treatment outcomes
and prognosis in patients with chronic viral hepatitis,
nonalcoholic fatty liver disease, or alcoholic hepatitis, as
well as other chronic liver diseases.References
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